NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on AzurRx BioPharma, Inc.  (NasdaqCM: AZRX)

Click here to view Full Argus Report.

Highlights, as conveyed by Argus Analyst Steve Silver, include:

COMPANY HIGHLIGHTS

 AZRX: Supporting Patients with Pancreas-Mediated Digestion Disorders

  • In our view, AzurRx’s lead product candidate, MS1819, provides a potential alternative to the current standard-of-care treatment for patients with gastrointestinal disorders orig­inating in the pancreas. The current standard of care is a porcine-based pancreatic enzyme replacement therapy (PERT), which exposes patients to the risk of infection, allergies, and potential adverse events when used at high doses; it and carries a high pill burden that can lead to patient noncompliance.
  • In December 2019 and January 2020, AzurRx raised $6.9 million in a private placement. In addition, the company received $1.8 million in R&D tax credits from the French gov­ernment for past research in March 2020. It also has access to up to $15 million in funding through an equity purchase program with Lincoln Park Capital. As such, we believe that AzurRx will have sufficient cash to advance MS1819 to value-inflection points in late 2020/early 2021.
  • We think that AzurRx’s recent valuation does not reflect the commercial prospects for the MS1819 asset given the product’s clear path to market. Our net present value analysis yields a fair value estimate for AZRX of $2.50 per share.

INVESTMENT THESIS (click here to view full Argus Equity Research Report & Investment Thesis)

About AzurRx BioPharma, Inc.  (NasdaqCM: AZRXwww.azurrx.com

AzurRx BioPharma Inc, founded in 2014, is a development-stage bio­pharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company’s lead asset is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis pa­tients). The company is headquartered in New York City, with scientific operations in Langlade, France and clinical operations in Hayward, California.

AZRX Contacts:

For more information:

AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn, NY 11226
Phone: (646)-699-7855
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations contact:

LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
1 International Place, Suite 1480 
Boston, MA 02110 
Phone: 617-430-7578 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

About Argus Research Corp. Headquartered in NYC, Argus Research (www.argusresearch.com) is a leading independent equity research firm (est. 1934)  ̶  providing fundamental and quantitative research coverage on more than 1,500 companies across all 11 sectors of the S&P 500, as well as macroeconomic and equity market forecasts, thematic research, model portfolios and pre-IPO research.  In addition, Argus has recently committed to providing a sponsored research solution for small & mid-cap companies seeking coverage.  Our Asset Management, Bank Trust, sell-side advisor and self-directed investor clients value Argus’s proprietary equity research methodology, analysis and commentary.  Argus’s Equity Research/earnings estimates are available on major research / earnings estimate aggregator platforms, including Bloomberg, Thomson Reuters, Factset and S&P Global.
   
For more Information re: Argus Research Services please contact:

Darrell Stone
646-747-5438
This email address is being protected from spambots. You need JavaScript enabled to view it.   

Argus Research Co. has received a flat fee from the company discussed in this report as part of a Sponsored Research agreement between Argus and the company. No part of Argus Research’s compensation is directly or indirectly related to the content of this assessment or to other opinions expressed in this report. Please refer to the full Argus report and the disclaimer for complete disclosures.